Effects of CTLA4-Ig treatment on circulating fibrocytes and skin fibroblasts from the same systemic sclerosis patients: an in vitro assay

BACKGROUND: Systemic sclerosis (SSc) is characterized by vasculopathy and progressive fibrosis. CTLA4-Ig (abatacept) is able to interact with the cell surface costimulatory molecule CD86 and downregulate the target cell. The aim of this study was to evaluate the in-vitro effects of CTLA4-Ig treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Cutolo, Maurizio, Soldano, Stefano, Montagna, Paola, Trombetta, Amelia Chiara, Contini, Paola, Ruaro, Barbara, Sulli, Alberto, Scabini, Stefano, Stratta, Emanuela, Paolino, Sabrina, Pizzorni, Carmen, Smith, Vanessa, Brizzolara, Renata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062881/
https://www.ncbi.nlm.nih.gov/pubmed/30053831
http://dx.doi.org/10.1186/s13075-018-1652-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062881/
https://www.ncbi.nlm.nih.gov/pubmed/30053831
http://dx.doi.org/10.1186/s13075-018-1652-6

Ejemplares similares